ArticleScientific reports2026
Immunoinformatics-based design and evaluation of a multi-epitope vaccine against Vibrio fluvialis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Immunoinformatics-Guided Computational Design and In Silico Validation of Multi-Epitope Vaccine Candidates Targeting Canine and Feline Parvoviruses.Microorganisms · 2026Article
- Integrative immunoinformatics and structural modeling for the rational design of a multi-epitope vaccine candidate against human cytomegalovirus.Scientific reports · 2026Article
- Integrative 16S rRNA characterization, pan-genome, and immunoinformatics approaches for the design of a multi-epitope vaccine against Bacillus cereus, a foodborne pathogen.World journal of microbiology & biotechnology · 2026Article
- Immunoinformatics-driven design of a multi-epitope vaccine against Seoul Virus: Structural, dynamic, and immunogenic profiling.Clinics (Sao Paulo, Brazil) · 2026Article
- Multi-epitope vaccine against nucleoprotein and envelopment polyprotein of Batai orthobunyavirus using molecular docking and molecular dynamics studies.Scientific reports · 2026Article
- In Silico identification of inhalable small-molecule IL-33/ST2 antagonists for severe type-2-high asthma endotypes.Scientific reports · 2026Article
- Immunoinformatics based design of a multiepitope vaccine targetingOpen medicine (Warsaw, Poland) · 2026Article
- Designing a multi-epitope vaccine against yellow fever virus using immunoinformatics approaches.Open medicine (Warsaw, Poland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Vibrio fluvialis is an emerging foodborne pathogen causing gastroenteritis and extraintestinal infections, representing a significant public health concern due to rising antimicrobial resistance and the absence of an approved vaccine. This study aimed to design a multi-epitope subunit vaccine against V. fluvialis using immunoinformatics and a standard multi-epitope vaccine design pipeline. Two surface-exposed immunogenic membrane proteins, ATP-dependent zinc metalloprotease FtsH and lytic murein transglycosylase F, were selected as antigenic targets. Ten epitopes, including four MHC class I, four MHC class II, and two B-cell epitopes, were predicted and assembled into a 246 amino acid vaccine construct. The construct showed an antigenicity score of 0.8610. Population coverage analysis indicated that these epitopes could potentially cover 99.97% of the global population. The vaccine exhibited favorable physicochemical properties, with an instability index of 33.18 and a GRAVY score of - 0.282, suggesting stability and hydrophilicity. The tertiary structure was modeled using AlphaFold3 and docked with Toll-like receptor 2, yielding a docking score of - 270.01. Molecular dynamics simulations for 100 ns suggested stability of the vaccine-TLR2 complex. Codon optimization indicated high expression potential in Escherichia coli, with a CAI value of 0.95. Overall, the vaccine showed strong in silico immunogenic potential and requires further experimental validation through in vitro and in vivo studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.